Characterization of human immunodeficiency virus type 1 (HIV-1) diversity and tropism in 145 patients with primary HIV-1 infection

Clinical Infectious Diseases

Volumn 53, Issue 12, 2011, Pages 1271-1279

  Rieder, Philip ^a   Joos, Beda ^a   Scherrer, Alexandra U ^a   Kuster, Herbert ^a   Braun, Dominique ^a   Grube, Christina ^a   Niederöst, Barbara ^a   Leemann, Christine ^a   Gianella, Sara ^a,c   Metzner, Karin J ^a   Böni, Jürg ^b   Weber, Rainer ^a   Günthard, Huldrych F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; VIRAL TROPISM; VIRUS ENVELOPE; VIRUS LOAD; VIRUS TRANSMISSION;

ADULT; AGED; CLUSTER ANALYSIS; ENV GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; FEMALE; GENETIC VARIATION; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PHYLOGENY; SEQUENCE ANALYSIS, DNA; SWITZERLAND; VIRAL TROPISM; YOUNG ADULT;

EID: 81855211496     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir725     Document Type: Article

References (39)

1. Salazar-Gonzalez JF, Bailes E, Pham KT, et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J Virol 2008; 82:3952-70. (Pubitemid 351521232)
2. Li H, Bar KJ, Wang S, et al. High multiplicity infection by HIV-1 in men who have sex with men. PLoS Pathog 2010; 6:e1000890.
3. Sagar M, Lavreys L, Baeten JM, et al. Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population. AIDS 2004; 18:615-9. (Pubitemid 38393460)
4. Long EM, Martin HL Jr., Kreiss JK, et al. Gender differences in HIV-1 diversity at time of infection. Nat Med 2000; 6:71-5. (Pubitemid 30048529)
5. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. J Virol 2010; 84: 6241-7.
6. Zhu T,Mo H,Wang N, et al. Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science 1993; 261:1179-81. (Pubitemid 23300886)
7. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 1997; 185:621-8. (Pubitemid 27098147)
8. Raymond S, Delobel P, Mavigner M, et al. CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. AIDS 2010; 24:2305-12.
9. Abbate I, Vlassi C, Rozera G, et al. Detection of quasispecies variants predicted to use CXCR4 by ultra-deep pyrosequencing during early HIV infection. AIDS 2011; 25:611-7.
10. Curlin ME, Zioni R, Hawes SE, et al. HIV-1 envelope subregion length variation during disease progression. PLoS Pathog 2010; 6:e1001228.
11. Fatkenheuer G, Nelson M, Lazzarin A, et al. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 2008; 359:1442-55.
12. Gulick RM, Lalezari J, Goodrich J, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008; 359: 1429-41.
13. Aceto L, Karrer U, Grube C, et al. [Primary HIV-1 infection in Zurich: 2002-2004]. Praxis (Bern 1994) 2005; 94:1199-205. (Pubitemid 41207523)
14. Metzner KJ, Rauch P, Von Wyl V, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis 2010; 201:1063-71.
15. Rieder P, Joos B, Von Wyl V, et al. HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. AIDS 2010; 24:1177-83.
16. Huber M, Fischer M, Misselwitz B, et al. Complement lysis activity in autologous plasma is associated with lower viral loads during the acute phase of HIV-1 infection. PLoS Med 2006; 3:e441.
17. Schmid A, Gianella S, Von Wyl V, et al. Profound depletion of HIV-1 transcription in patients initiating antiretroviral therapy during acute infection. PLoS One 2010; 5:e13310.
18. Gianella S, vonWyl V, Fischer M, et al. Effect of early antiretroviral therapy during primary HIV-1 infection on cell-associated HIV-1 DNA and plasma HIV-1 RNA. Antivir Ther 2011; 16:535-45.
19. Fischer M, Huber W, Kallivroussis A, et al. Highly sensitive methods for quantitation of human immunodeficiency virus type 1 RNA from plasma, cells, and tissues. J Clin Microbiol 1999; 37:1260-4. (Pubitemid 29187780)
20. Joos B, Trkola A, Fischer M, et al. Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions. J Virol 2005; 79:9026-37. (Pubitemid 40934813)
21. Sing T, Low AJ, Beerenwinkel N, et al. Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 2007; 12: 1097-106. (Pubitemid 350114990)
22. Harada S, Koyanagi Y, Yamamoto N. Infection of HTLV-III/LAV in HTLV-I-carrying cells MT-2 and MT-4 and application in a plaque assay. Science 1985; 229:563-6. (Pubitemid 16239336)
23. Morner A, Bjorndal A, Albert J, et al. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J Virol 1999; 73:2343-9. (Pubitemid 29098139)
24. Japour AJ, Fiscus SA, Arduino JM, Mayers DL, Reichelderfer PS, Kuritzkes DR. Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol 1994; 32:2291-4. (Pubitemid 24258484)
25. Trkola A, Ketas T, Kewalramani VN, et al. Neutralization sensitivity of human immunodeficiency virus type 1 primary isolates to antibodies and CD4-based reagents is independent of coreceptor usage. J Virol 1998; 72:1876-85. (Pubitemid 28100739)
26. Katoh K, Toh H. Recent developments in the MAFFT multiple sequence alignment program. Brief Bioinform 2008; 9:286-98. (Pubitemid 351890825)
27. Katoh K, Misawa K, Kuma K, Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res 2002; 30:3059-66. (Pubitemid 34851225)
28. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-9. (Pubitemid 47236692)
29. Von Wyl V, Yerly S, Boni J, et al. Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. Arch Intern Med 2007; 167:1782-90. (Pubitemid 47403067)
30. Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871-9. (Pubitemid 37070272)
31. Haaland RE, Hawkins PA, Salazar-Gonzalez J, et al. Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS Pathog 2009; 5: e1000274.
32. Sagar M, Kirkegaard E, Long EM, et al. Human immunodeficiency virus type 1 (HIV-1) diversity at time of infection is not restricted to certain risk groups or specific HIV-1 subtypes. J Virol 2004; 78: 7279-83. (Pubitemid 38781567)
33. Abrahams MR, Anderson JA, Giorgi EE, et al. Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants. J Virol 2009; 83:3556-67.
34. Arien KK, Abraha A, Quinones-Mateu ME, Kestens L, Vanham G, Arts EJ. The replicative fitness of primary human immunodeficiency virus type 1 (HIV-1) group M, HIV-1 group O, and HIV-2 isolates. J Virol 2005; 79:8979-0.
35. Poss M, Martin HL, Kreiss JK, et al. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol 1995; 69:8118-22.
36. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-75. (Pubitemid 46185274)
37. Koot M, Vos AH, Keet RP, et al. HIV-1 biological phenotype in longterm infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992; 6:49-54.
38. Frange P, Galimand J, Goujard C, et al. High frequency of X4/DM-tropic viruses in PBMC samples from patients with primary HIV-1 subtype-B infection in 1996-2007: the French ANRS CO06 PRIMO Cohort Study. J Antimicrob Chemother 2009; 64:135-41.
39. Frange P, Chaix ML, Raymond S, et al. Low frequency of CXCR4-using viruses in patients at the time of primary non-subtype-B HIV-1 infection. J Clin Microbiol 2010; 48:3487-91.